摘要
目的 :探讨培哚普利对充血性心力衰竭 (CHF)患者血浆细胞间粘附因子 1(sICAM 1)水平的影响及心脏保护机制。 方法 :用酶联免疫方法检测 42例服用培哚普利的CHF患者、42例常规治疗CHF患者治疗前后及 30例健康者血浆中sICAM 1水平。 结果 :① 84例CHF患者血浆中sICAM 1为 ( 5 87.6± 15 2 .1) μg/L ,较健康者 ( 16 7.4± 34.6 ) μg/L显著增高 ( P<0 .0 0 1) ,且随着心功能损害程度加重而升高 ,各组间比较差异有显著性意义 (P <0 .0 5 )。②CHF培哚普利治疗组与常规治疗组治疗前后血浆中sICAM 1浓度〔分别为 ( 5 91.8± 15 5 .2 )、( 332 .1± 115 .8) μg/L ;( 5 80 .0± 134.4)、( 4 2 3.1± 118.1) μg/L〕水平差异有非常显著性意义 (P <0 .0 1) ,且培哚普利治疗组较常规治疗组治疗后血浆中sICAM 1降低更为明显 (P <0 .0 1)。 结论 :培哚普利具有抑制CHF患者sICAM 1水平的作用 ,从而减缓心室重塑的进程 ,保护和改善心功能。
Objective:To investigate the effects of perindopril on cardiac function and plasma levels of soluble intercellular adhesion molecule 1(sICAM1) in patients with congestive heart failure (CHF). Method:The levels of plasma sICAM1 were determined by enzyme-linked immunosorbent assay (ELISA) in 84 CHF cases (42 of whom were treated by perindopril and the rest were treated by conventional treatment), and in 30 healthy cases as control group.Result:①The levels of sICAM1 in all CHF cases were much higher than those of the control cases[ ( 587.6± 152.1)μg/L vs ( 167.4± 34.6)μg/L, P< 0.001 ] .②The plasma levels of sICAM1 significantly decreased 2 weeks after the treatment in both perindopril group and conventional group [from (591.8±155.2)μg/L to (332.1±115.8)μg/L;from (580.0±134.4)μg/L to ( 423.1± 118.1)μg/L respectively,P< 0.01]. Compared with those in conventional group, the sICAM1 levels in perindopril group were significantly lower (P< 0.01).Conclusion:The results show that perindopril may play an important role of protecting and improving cardiac function by decreasing sICAM1 levels and remitting ventricular remodeling in patients with CHF.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2002年第2期51-53,共3页
Journal of Clinical Cardiology
